AU2020272074A1 - Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins - Google Patents

Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins Download PDF

Info

Publication number
AU2020272074A1
AU2020272074A1 AU2020272074A AU2020272074A AU2020272074A1 AU 2020272074 A1 AU2020272074 A1 AU 2020272074A1 AU 2020272074 A AU2020272074 A AU 2020272074A AU 2020272074 A AU2020272074 A AU 2020272074A AU 2020272074 A1 AU2020272074 A1 AU 2020272074A1
Authority
AU
Australia
Prior art keywords
egfr
seq
car
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020272074A
Other languages
English (en)
Inventor
Zev BINDER
Michael MILONE
Donald O'ROURKE
Rahika THOKALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2020272074A1 publication Critical patent/AU2020272074A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AU2020272074A 2019-04-12 2020-04-11 Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins Pending AU2020272074A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833456P 2019-04-12 2019-04-12
US62/833,456 2019-04-12
US201962892343P 2019-08-27 2019-08-27
US62/892,343 2019-08-27
PCT/US2020/027859 WO2020210768A1 (en) 2019-04-12 2020-04-11 Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins

Publications (1)

Publication Number Publication Date
AU2020272074A1 true AU2020272074A1 (en) 2021-11-25

Family

ID=72751475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020272074A Pending AU2020272074A1 (en) 2019-04-12 2020-04-11 Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins

Country Status (5)

Country Link
US (1) US20220184129A1 (https=)
EP (1) EP3952885A4 (https=)
JP (2) JP2022526856A (https=)
AU (1) AU2020272074A1 (https=)
WO (1) WO2020210768A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
EP4344409A4 (en) * 2021-07-01 2025-05-21 Duke University D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same
US20240285757A1 (en) * 2021-08-06 2024-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2013327136A1 (en) * 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3447072A3 (en) * 2013-03-05 2019-05-22 Baylor College of Medicine Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014201378A1 (en) * 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
JP6682509B2 (ja) * 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
SG11201805449PA (en) * 2015-12-28 2018-07-30 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
MY209117A (en) * 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
WO2017181101A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric alloantigen receptor t cells
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CN110564749B (zh) * 2018-06-05 2024-01-05 上海恒润达生生物科技股份有限公司 靶向egfr的嵌合抗原受体及其用途
US20230158071A1 (en) * 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy

Also Published As

Publication number Publication date
JP2022526856A (ja) 2022-05-26
WO2020210768A1 (en) 2020-10-15
JP2025102823A (ja) 2025-07-08
EP3952885A4 (en) 2023-01-18
EP3952885A1 (en) 2022-02-16
US20220184129A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
US20250026824A1 (en) Human alpha-folate receptor chimeric antigen receptor
JP7526097B2 (ja) 前立腺特異的膜抗原ｃａｒおよびその使用方法
US20240158506A1 (en) Methods to protect transplanted tissue from rejection
US12410232B2 (en) Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
US20250084376A1 (en) Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20240131160A1 (en) Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes
JP2025102823A (ja) 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法
US20220168407A1 (en) Use of tumor-independent antigens in immunotherapies
US20210322471A1 (en) In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20250177442A1 (en) Boosting chimeric antigen receptor cells in the blood
US20260103523A1 (en) BW6 Specific CAR Designed To Protect Transplanted Tissue From Rejection
HK40127569A (zh) 用於肿瘤治疗的car修饰剂的产生